Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2016 Nov 5;78(6):1245–1252. doi: 10.1007/s00280-016-3183-7

Fig. 2.

Fig. 2

Axial PET/CT slice with increased SUV in right paratracheal lymph node (white arrow). Note reduced SUV at peak drug in both cycle 1 and cycle 3 which subsides by the end of washout. C1 cycle 1, C3 cycle 3